Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience

Vijaya R. Bhatt; Fausto R. Loberiza; Lynette M. Smith; James O. Armitage; Timothy C. Greiner; Martin Bast; Matthew A. Lunning; Philip J. Bierman; Julie M. Vose; R. Gregory Bociek

doi:10.3109/10428194.2015.1094801

Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience

Vijaya R. Bhatt, Fausto R. Loberiza, Lynette M. Smith, James O. Armitage, Timothy C. Greiner, Martin Bast, Matthew A. Lunning, Philip J. Bierman, Julie M. Vose, R. Gregory Bociek

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

Original language	English (US)
Pages (from-to)	1327-1334
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	57
Issue number	6
DOIs	https://doi.org/10.3109/10428194.2015.1094801
State	Published - Jun 2 2016

Keywords

Blastoid variant
diffuse subtype
intensive induction therapy
mantle cell lymphoma
nodular subtype
stem cell transplantation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2015.1094801

Cite this

Bhatt, V. R., Loberiza, F. R., Smith, L. M., Armitage, J. O., Greiner, T. C., Bast, M., Lunning, M. A., Bierman, P. J., Vose, J. M., & Bociek, R. G. (2016). Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience. Leukemia and Lymphoma, 57(6), 1327-1334. https://doi.org/10.3109/10428194.2015.1094801

@article{8d80df2696ee464683e95b561a9ba359,

title = "Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience",

abstract = "The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.",

keywords = "Blastoid variant, diffuse subtype, intensive induction therapy, mantle cell lymphoma, nodular subtype, stem cell transplantation",

author = "Bhatt, {Vijaya R.} and Loberiza, {Fausto R.} and Smith, {Lynette M.} and Armitage, {James O.} and Greiner, {Timothy C.} and Martin Bast and Lunning, {Matthew A.} and Bierman, {Philip J.} and Vose, {Julie M.} and Bociek, {R. Gregory}",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor & Francis.",

year = "2016",

month = jun,

day = "2",

doi = "10.3109/10428194.2015.1094801",

language = "English (US)",

volume = "57",

pages = "1327--1334",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma

T2 - A Nebraska Lymphoma Study Group Experience

AU - Bhatt, Vijaya R.

AU - Loberiza, Fausto R.

AU - Smith, Lynette M.

AU - Armitage, James O.

AU - Greiner, Timothy C.

AU - Bast, Martin

AU - Lunning, Matthew A.

AU - Bierman, Philip J.

AU - Vose, Julie M.

AU - Bociek, R. Gregory

PY - 2016/6/2

Y1 - 2016/6/2

N2 - The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

AB - The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT) was similar (p = 0.44) between blastoid, diffuse and nodular subtypes. At 5 years, blastoid and diffuse subtypes had worse OS (overall p = 0.005) compared to nodular subtype. In multivariate analysis, the blastoid and diffuse subtypes had similar risk of death (p = 0.14) whereas the nodular subtype had a lower risk compared to blastoid (HR 0.48, 95% CI 0.27-0.87, p = 0.01). The use of SCT was associated with lower risk of death. In univariate analysis, blastoid subtype had better OS with intensive upfront therapy. In conclusion, the OS of blastoid subtype is worse than nodular MCL but may improve with the use of SCT and probably intensive induction therapy.

KW - Blastoid variant

KW - diffuse subtype

KW - intensive induction therapy

KW - mantle cell lymphoma

KW - nodular subtype

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84945207628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945207628&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1094801

DO - 10.3109/10428194.2015.1094801

M3 - Article

C2 - 26377137

AN - SCOPUS:84945207628

SN - 1042-8194

VL - 57

SP - 1327

EP - 1334

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 6

ER -

Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: A Nebraska Lymphoma Study Group Experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this